Krka has maintained strong growth in the past nine months despite ongoing questions surrounding its significant presence in Russia and foreign currency risks linked to the rouble.
MSN Laboratories has struck a patent-litigation settlement deal with BeiGene that will allow it to launch its zanubrutinib generic rival to Brukinsa in the US from 2037.
Dr Reddy’s Laboratories has spoken at length about its ability to make most of its GLP-1 APIs and formulations in-house, as it looks to be a ‘day one’ player for opportunities including semaglutide.
With most regions reporting double-digit growth in the second quarter, analysts’ opinions differ about Lupin’s future.
Having previously set itself a deadline of the end of November to strike a licensing deal for one of two biosimilar candidates – or risk failing to meet its working capital requirements – Sweden’s Xbrane has now announced a global licensing partnership with Intas for its nivolumab Opdivo rival, with just days to spare.
As it delivered financial first-half results, Japan’s Towa raised its full-year forecast after seeing continued strong demand in Japan and in anticipation of a lower than predicted R&D spend.
Amneal knows what it wants and is determined to get it. With more and more complex products being added to its portfolio, the firm marks another “terrific” quarterly performance.
Reflecting the company’s acquisition of Alimera Sciences, ANI Pharmaceuticals has shared the first results that included new assets as it pushes to a more diversified business strategy.
As Fresenius delivered its third-quarter results, the firm’s Fresenius Kabi division celebrated sales growth of two-thirds in its Biopharma biosimilars segment amid several solid increases seen in Q3.
Aurobindo is looking to finally put a key manufacturing disruption behind it in Europe, enabling the firm to gain traction for some of its early biosimilar filings.
Viatris provided several updates for its launch plans in 2025 during the company’s third-quarter earnings call.
After past challenges caused by reimbursement drug price cuts imposed by the Japanese government, Chemiphar has managed to keep its operating profits in the black in the second quarter of its 2024 financial year.
Fresenius Kabi-controlled mAbxience has struck a deal with Servier’s Egis Pharmaceutical to commercialize two biosimilar candidates in multiple central and eastern European markets.
Sandoz has ticked off a pair of corporate milestones, including the opening of a new UK device development center which will serve as a global hub for developing advanced delivery devices supporting the firm’s extensive pipeline.
Hikma says that its acquisition of Xellia’s finished dosage form business and a key contract manufacturing agreement in generics have kept its business on track to meet its full-year forecasts.
After a “solid start to the year”, Organon has delivered on analyst expectations with its third quarter results, despite ongoing questions surrounding future growth and market penetration of key compounds. Meanwhile, the firm’s filing for a biosimilar rival to Prolia/Xgeva has been accepted by the FDA.
Meitheal has announced a licensing agreement with parent company Hong Kong King-Friend to add another three biosimilars to its pipeline for the US market.
A significant divestment in the works, complex generic launches, a mammoth antitrust fine in Europe – Teva’s Q3 was busy and bustling, led by strong, double-digit top-line growth and a further rise in guidance for 2024.
Zentiva has responded to recent rumors that owner Advent International may be looking to sell the firm in a deal worth as much as €5bn.
After under-delivering on already muted expectations, Biocon's optimistic future was overshadowed by pending FDA inspection outcomes on two of its facilities.